Articles by tag: nejm

Sunvozertinib outperforms chemotherapy in EGFR exon20ins lung cancer

NEJM: oral sunvozertinib reduces the risk of progression by 35% in NSCLC with EGFR exon20ins mutation. Full analysis of efficacy, toxicity and drug availability. Learn more.

Cholesterol gene therapy VERVE-102: NEJM data, LDL reduction by 62%

NEJM published phase 1b results of gene therapy VERVE-102: LDL reduction by 62% after a single injection. Analysis of efficacy, risks, and prospects for patients with hypercholesterolemia. Read more.

Telitacicept in IgA Nephropathy: Phase 3 Results in NEJM

Interim Results of TELIGAN: Telitacicept Reduces Proteinuria by 58.9% vs 8.8% Placebo. Learn How the New Dual Inhibitor Is Changing the IgA Nephropathy Market.